{"filing":{"accession_number":"0001437749-26-022088","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"mbrx20260630_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926022088/mbrx20260630_8k.htm"},"events":[{"id":14871,"run_id":13255,"accession_number":"0001437749-26-022088","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This disclosure announces positive preliminary interim efficacy results from the Phase 2/3 MIRACLE trial of Annamycin for relapsed/refractory AML, showing both treatment arms outperforming control on the primary endpoint of complete remission (43% and 36% vs. 12%). While the results are clinical/operational in nature rather than financial, they represent a material milestone in the company's lead drug development program that would affect a reasonable investor's assessment of the registrant's prospects. This is not an earnings release (no financial results), but rather a material clinical trial milestone disclosure that fits best under operational_other as a significant product/regulatory development.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12441,"accession_number":"0001437749-26-022088","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces positive preliminary interim efficacy results from the Phase 2/3 MIRACLE trial of Annamycin for relapsed/refractory AML, showing both treatment arms outperforming control on the primary endpoint of complete remission (43% and 36% vs. 12%). While the results are clinical/operational in nature rather than financial, they represent a material milestone in the company's lead drug development program that would affect a reasonable investor's assessment of the registrant's prospects. This is not an earnings release (no financial results), but rather a material clinical trial milestone disclosure that fits best under operational_other as a significant product/regulatory development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:31:38.212370+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12441,"accession_number":"0001437749-26-022088","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces positive preliminary interim efficacy results from the Phase 2/3 MIRACLE trial of Annamycin for relapsed/refractory AML, showing both treatment arms outperforming control on the primary endpoint of complete remission (43% and 36% vs. 12%). While the results are clinical/operational in nature rather than financial, they represent a material milestone in the company's lead drug development program that would affect a reasonable investor's assessment of the registrant's prospects. This is not an earnings release (no financial results), but rather a material clinical trial milestone disclosure that fits best under operational_other as a significant product/regulatory development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:31:38.212370+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-06-30"}]}